Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Change in Cash (2018 - 2025)

10x Genomics (TXG) has disclosed Change in Cash for 8 consecutive years, with $41.3 million as the latest value for Q4 2025.

  • Quarterly Change in Cash rose 176.27% to $41.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $129.9 million through Dec 2025, up 953.64% year-over-year, with the annual reading at $129.9 million for FY2025, 953.64% up from the prior year.
  • Change in Cash hit $41.3 million in Q4 2025 for 10x Genomics, up from $35.0 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $112.4 million in Q1 2023 to a low of -$276.0 million in Q1 2022.
  • Historically, Change in Cash has averaged -$10.7 million across 5 years, with a median of -$6.2 million in 2023.
  • Biggest five-year swings in Change in Cash: tumbled 906.61% in 2022 and later surged 1041.88% in 2025.
  • Year by year, Change in Cash stood at -$13.0 million in 2021, then decreased by 9.27% to -$14.2 million in 2022, then soared by 413.77% to $44.5 million in 2023, then crashed by 221.43% to -$54.1 million in 2024, then surged by 176.27% to $41.3 million in 2025.
  • Business Quant data shows Change in Cash for TXG at $41.3 million in Q4 2025, $35.0 million in Q3 2025, and $20.7 million in Q2 2025.